Analyst Price Target is $7.46
▲ +366.41% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Ardelyx in the last 3 months. The average price target is $7.46, with a high forecast of $15.00 and a low forecast of $2.00. The average price target represents a 366.41% upside from the last price of $1.60.
Current Consensus is
The current consensus among 8 investment analysts is to buy stock in Ardelyx. This Buy consensus rating has held steady for over two years.
Ardelyx, Inc., a biopharmaceutical company, develops and sells medicines for the treatment of kidney and cardiorenal diseases in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase 3 clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase 3 clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. It also develops RDX013, a small molecule potassium secretagogue program that is in Phase 2 clinical trial for the treatment of patients with hyperkalemia; and RDX020, a small molecule program for the treatment of metabolic acidosis. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Fremont, California.